Read more
Cancer incidences increase in people living with HIV/AIDS. Over 2 million people currently live with HIV/AIDS in the US. This number will increase as HAART prolongs the average lifespan and as (at least in some states) the number of new HIV infections increase again. As this population ages their incidence rates for cancer will increase, as well.
Recently, new rational targets for cancer therapy have emerged. But their application to the care of HIV+ patients is slow, because of concerns about the weakened immune status of the patients, because of possible drug interactions with HAART and because some of the AIDS defining cancer are rare.
List of contents
The Epidemiology of Cancer in People with HIV.- Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies.- HIV-Related Cancer Management in Resource-Limited Settings: A Case Study of Malawi.- Immunology of HIV-Associated Kaposi Sarcoma.- Targeting Signal Transduction Pathways for the Treatment of Kaposi Sarcoma.- Role of NF-?B Inhibitors in HIV-Related Malignancies.- The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV, EBV)-Associated, AIDS-Related Tumors.- Viral Interleukin-6: Molecular Biology and Pathogenesis.- Targeting the PI3K/Akt/mTOR Pathway in AIDS-Associated Malignancies.- Restoration of p53 Function by MDM2 Inhibition: Potential Strategy to Treat KSHV-Associated Malignancies.- Interferon in Kaposi's Sarcoma Biology and Therapy.- Metronomic Therapy for HIV-Associated Malignancies.- Targeting EGFR in HPV-Associated Cancer.- Cidofovir Against Human Papillomavirus-Associated Diseases.
Summary
Cancer incidences increase in people living with HIV/AIDS. Over 2 million people currently live with HIV/AIDS in the US. This number will increase as HAART prolongs the average lifespan and as (at least in some states) the number of new HIV infections increase again. As this population ages their incidence rates for cancer will increase, as well.
Recently, new rational targets for cancer therapy have emerged. But their application to the care of HIV+ patients is slow, because of concerns about the weakened immune status of the patients, because of possible drug interactions with HAART and because some of the AIDS defining cancer are rare.
